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ICER would be $53,964/QALY and the W would be $-362 (SD
3322). If the subjects were to improve after dropout, the ICER
would be $29,475/QALY and the W would be $3434 (SD 3309).
CONCLUSIONS: The results of cost-effectiveness analysis are
fairly robust to the choice of imputation scenario. While point
estimates indicate that over 4 years pramipexole is a cost-
effective alternative to levodopa, signiﬁcant statistical uncer-
tainty exists. The uncertainty associated with the assumptions
regarding post-dropout Qol is dwarfed by the uncertainty asso-
ciated with the ICER estimate.
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The success of population screening for CRC depends largely on
public uptake. Available strategies differ in multiple dimensions
of process and outcome. OBJECTIVE: To measure patient pref-
erences for CRC screening attributes and estimate willingness to
pay (WTP) for changes in attribute levels using a discrete choice
experiment (“conjoint analysis”). METHODS: Six key attributes
of CRC screening strategies were identiﬁed through structured
focus groups. Questionnaires included 10 choice sets based on a
fractional factorial design to maximize D efﬁciency. Surveys 
were mailed to a random sample of patients aged 40–60 years
from an Ontario primary care network (response rate = 51%
(547/1074), 88% of whom completed all 10 choice sets (n =
485)); b coefﬁcients from regression analyses estimated the mar-
ginal utilities of attribute levels from which WTP was calculated.
Differences among subgroups were tested using likelihood ratio
tests. RESULTS: Respondents had the strongest preferences for
sensitivity, with the highest utility for high sensitivity and the
lowest utility for low sensitivity. Individuals would be willing to
pay an additional CDN$910 (~US$640) for a test with high vs.
low sensitivity. Following sensitivity, respondents had the highest
preferences (in descending order) for speciﬁcity, preparation,
pain, and price. Preferences differed signiﬁcantly by gender, age
(<50yrs vs. >50yrs), income (<$50,000 vs. >$50,000) and edu-
cation (high school or less versus college or higher). In follow-
up questions for each choice set where individuals were asked if
they would prefer no test, 26% of respondents chose no testing
in more than 5 of their 10 choice sets. CONCLUSIONS: Results
show a wide range of marginal utility for attribute levels of CRC
screening tests, and many respondents preferred no test. Better
understanding of patient preferences can help improve the
design, promotion and uptake of CRC screening programs.
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OBJECTIVES: To quantify the cost effectiveness of updated clin-
ical guidelines for risk screening and prevention of cardiovascu-
lar disease (CVD) with “statin” therapy in individuals free of
cardiovascular disease. METHODS: Risk proﬁles were collected
in 1992–1993 for 4704 men age 35–84y and 1216 women age
45–84y without CVD. Five-year risk of a cardiovascular hospi-
tal admission for each individual was estimated using a locally
validated Framingham risk equation. The predicted number of
incident events in 5 years was scaled to the 2001 NZ census pop-
ulation and integrated over age groups. In the base case, costs,
beneﬁts and cost effectiveness were estimated at screening age
thresholds of 45 for men and 55 for women (10 years younger
for smokers); concurrent treatment thresholds of 15% 5-year
cardiovascular risk and TC/HDLc = 4.5; and 5% discount rate.
RESULTS: In the NZ population of 784K men age 35–84y and
558K women age 45–84y, 72K men and 53K women would be
eligible for prophylaxis. Compared to no intervention, 5y pro-
phylaxis with 84% treatment adherence at a 15% treatment
threshold would avert 6716 incident cardiovascular events and
add 17,205 life years or 21,317 QALYs at an incremental cost
of $NZ70M. The base case ICER is $10,459 per event avoided,
$4083 per LYG or $3295 per QALY and it is sensitive to the
threshold lipid ratio, screening and treatment ages, risk thresh-
old, treatment efﬁcacy, 5y cardiovascular fatality, statin unit
price and the discount rate. CONCLUSIONS: Screening and
prophylaxis with statins is very cost effective at current drug
prices and clinically realistic screening and treatment thresholds.
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OBJECTIVE: To compare mammography screening in rural and
urban areas and to assess the effect of various predisposing and
enabling factors on mammography screening. METHODS: Ret-
rospective self-reported cross-sectional data from Behavioral
Risk Factor Surveillance System (BRFSS) for year 2000 along
with county level contextual variables from area resource ﬁle
(ARF) were used in the analysis. The analysis was restricted to
females between 40–69 years of age. Logistic regression analysis
was performed using an indicator of mammography screening as
a dependent variable and race, age, rural dummy as independent
variables. Series of multiple logistic regressions adding predis-
posing and enabling factors consecutively to this model were
conducted. All the results were adjusted for complex survey
design. RESULTS: Seventy eight percent of women reported
having had a mammography within the last two years for routine
check up. Women living in rural area were less likely to be
screened for mammography as compared to women residing in
urban areas (OR = 0.80, CI = 0.72–0.86). This difference in
screening no longer persisted after controlling for predisposing
(smoking status, education level), enabling (income, insurance
status) and contextual level enabling factors (physician popula-
tion ratio). In general, women with higher education and better
ﬁnancial condition were more likely to screen. CONCLUSIONS:
Insurance status was one of the major determinants of mam-
mography screening for females residing in rural area. Avail-
ability of health care services also had an impact on screening
rates. In an environment where rural areas are faced with short-
age of health care services, the active participation of health care
workers like physicians in advocating use of screening services
becomes crucial.
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OBJECTIVES: The purpose of this study was to determine
whether screening for the a-adducin gene variant among hyper-
